Jade Biosciences Statistics
Total Valuation
JBIO has a market cap or net worth of $1.19 billion. The enterprise value is $881.46 million.
| Market Cap | 1.19B |
| Enterprise Value | 881.46M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JBIO has 59.36 million shares outstanding.
| Current Share Class | 59.36M |
| Shares Outstanding | 59.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +7.01% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 71.50% |
| Float | 44.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.34 |
| P/TBV Ratio | 4.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.29, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.29 |
| Quick Ratio | 13.96 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.11 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -44.96% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, JBIO has paid $74,000 in taxes.
| Income Tax | 74,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +130.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +130.54% |
| 50-Day Moving Average | 20.23 |
| 200-Day Moving Average | 16.25 |
| Relative Strength Index (RSI) | 47.26 |
| Average Volume (20 Days) | 1,033,666 |
Short Selling Information
The latest short interest is 8.15 million, so 13.73% of the outstanding shares have been sold short.
| Short Interest | 8.15M |
| Short Previous Month | 4.95M |
| Short % of Shares Out | 13.73% |
| Short % of Float | 18.26% |
| Short Ratio (days to cover) | 4.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -133.60M |
| Pretax Income | -129.54M |
| Net Income | -95.10M |
| EBITDA | -133.57M |
| EBIT | -133.60M |
| Earnings Per Share (EPS) | -$2.11 |
Balance Sheet
The company has $311.30 million in cash and $808,000 in debt, with a net cash position of $310.49 million or $5.23 per share.
| Cash & Cash Equivalents | 311.30M |
| Total Debt | 808,000 |
| Net Cash | 310.49M |
| Net Cash Per Share | $5.23 |
| Equity (Book Value) | 296.46M |
| Book Value Per Share | 6.01 |
| Working Capital | 296.23M |
Cash Flow
In the last 12 months, operating cash flow was -$100.01 million and capital expenditures -$196,000, giving a free cash flow of -$100.21 million.
| Operating Cash Flow | -100.01M |
| Capital Expenditures | -196,000 |
| Depreciation & Amortization | 35,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -100.21M |
| FCF Per Share | -$1.69 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
JBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -7.98% |
| FCF Yield | -8.41% |
Analyst Forecast
The average price target for JBIO is $48.50, which is 141.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $48.50 |
| Price Target Difference | 141.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |